In particular, de novo gain-of-function in NLRC4 could be identified in patients presenting with a range of clinical manifestations of autoinflammation and macrophage activation syndrome, including severe very early onset enterocolitis (103, 104). Here, NLRC4 is linked to macrophage activation syndrome.